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ABSTRACT 
 
Plasmablastic lymphoma is a rare and diffuse large B cell lymphoma. It is rarely presents as oral cavity tu-
mour, normally seen in HIV or immunocompromised patients. Here we report a case of plasmablastic lym-
phoma in a 82 year old immunocompetent patient. The patient’s chief complaint was swelling in the left 
lower mandible for last few months. Prior to the swelling, the patient had backache problems which was 
investigated and undiagnosed. The oral lesion responded well to chemotherapy and got regressed. The fol-
lowing presentation discusses clinical, radiological, histological, immunological features and its manage-
ment and prognosis. 
Keywords: Multilocular radiolucency; posterior jaw tumor; rare jaw tumor; lymphoma; NHL; plasmacy-
toma; plasmablastic. 
ISSN: Awaiting 
Case Report 
Corresponding Author 
Name: Dr. K.V. Ramana Reddy  
Email: rrkanapuram@yahoo.com 
Contact: +91- 
Article Info 
Received on: 25-04-2020 
Revised on: 14-05-2020 
Accepted on:  
 
Copyright© 2020, K.V. Ramana Reddy, et al., 
Plasmablastic lymphoma of the oral cavity in a 
immunocompetent patient: A case report, Pro-
duction and hosting by Rubatosis Publications. 
All rights reserved. 
INTRODUCTION 
Non Hodgkin lymphoma (NHL) comprises of a group 
of malignant lymphoproliferative diseases. It often 
disseminates into extranodal sites (33%). Oral cavity 
involvement accounts for 0.1 to 5 % of all extra nodal 
lymphomas with palate being the most common 
site[1]. Plasmablastic lymphoma (PBL) is a rare and 
diffuse large B cell lymphoma and was initially de-
scribed by Delecluse et al[2] in year 1997. It is aggres-
sive subtype of non – Hodgkin lymphoma, frequently 
arises in the oral cavity of immunocompromised pa-
tients like HIV and latent EBV infection[1,3]. It accounts 
for 2.6% of all HIV related non –Hodgkin lympho-
mas[4]. PBL is commonly associated with immuno-
compromised patients and rarely seen in immuno-
competent patients. 
PBL are noted to be rapidly progressive with a high 
mitotic index[5] and shows rapid growth. Diagnosis of 
PBL is a diagnostic challenge due to its clinical and 
microscopic resemblance to other categories of non – 
Hodgkin lymphoma and plasmacytoma[6]. Therefore, 
demonstration using distinguishing patterns of ex-
pression of immunohistochemical markers which is 
an essential component of the diagnostic protocol6.  
PBL patients have been treated heterogeneously, 
with a combination of chemotherapy, radiotherapy 
and surgery and the prognosis is poor, with the death 
rate of approximately 60 % at 1 year[7]. 
Here, we present a case report of PBL which affected 
the body of the mandible in a non – HIV elderly pa-
tient. 
 
Figure 1: Intraoral picture showing a solitary sessile 
swelling measuring approximately 3 cm × 2.5 cm in-
volving left mandibular body 
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CASE REPORT 
A 82 year old male reported to our department of 
Oral and maxillofacial surgery with the chief com-
plaint of slow growing swelling in the left posterior 
mandibular region over last 6 months duration. 
Patient had no history of pus discharge, spontaneous 
bleeding and paraesthesia. 
On taking past medical history, patient had visited or-
thopaedic surgeon for back pain which was affecting 
his daily activity for past 6 months. Patient was ad-
viced undergo MRI for further investigation, which 
showed generalised involvement of long bones. Sim-
ultaneously he reported to our department with the 
complaint of swelling on left side of face. 
On extra-oral examination, a diffuse, ill-defined swell-
ing was present on the left side of mandible with no 
change in overlying skin colour and texture. On pal-
pation, swelling was firm, diffuse, non-tender, non-
fluctuant, non-compressible and their was no local 
rise in temperature noted. 
Intraoral examination revealed a solitary sessile 
swelling measuring approximately 3 cm × 2.5 cm in 
size was observed involving left mandibular body ex-
tending from lower 1st premolar up to ramus of man-
dible anterioposteriorly with buccolingual expansion 
(Figure 1). The overlying mucosa was normal in ap-
pearance with no change in colour and their was no 
signs of ulceration and pulsation. 
On palpation, there was no significant rise in the tem-
perature of overlying mucosa. Swelling was non ten-
der, firm, non-fluctuant and non-compressible. 
Pathological mobility was seen in relation to mandib-
ular 1st and 2nd molar. 
On radiographic examination, OPG reveals multiple 
locular radiolucency without sclerotic borders pre-
sent in left and right body of mandible (Figure 2). On 
left side root resorption was observed in relation to 
lower 1st and 2nd pre molars and molars. 
 
Figure 2: Showing OPG reveals multiple locular radio-
lucency present in left and right body of mandible 
On the basis of clinical and radiological features pro-
visional diagnosis of ameloblastoma, ameloblastic 
carcinoma was made. 
An incisional biopsy was performed under L.A and 
microscopic examination revealed a tumor composed 
of sheets and nests of homogenous population of 
plasmacytoid cells with intervening delicate fibrous 
septae. Tumor cells shows abundant basophilic cyto-
plasm with occasional paranuclear and, eccentric nu-
clei and open chromatin. No significant cytologic 
atypia noted, only occasional mitosis present. Areas 
of haemorrhage seen with no evidence of atypical mi-
tosis. A provisional histological diagnosis of 
plasmacytoma was made and it was advised for im-
munohistochemical staining. 
Immunohistochemical (IHC) staining was performed 
and tumor cells expressed strong positivity for CD 
138 and patchy positivity for CD 20 (Figure 4 & Fig-
ure 5). Based on these findings a final diagnosis of 
PBL was made. The routine blood investigation were 
under normal limits and patient was seronegative for 
HIV.  
Patient was referred to oncology unit, were conserva-
tive treatment was proposed and carried out. Chem-
otherapy was initiated with Bortezomib 2mg subcu-
taneously on days 1, 8, 15 and 22. The lesion re-
gressed after the treatment (Figure 3) and patient 
was in stable condition while discharging. 
 
Figure 3: Picture shows complete regression of the le-
sion after 3 cycles of chemotherapy  
 
Figure 4: IHC staining shows positive CD138 & Kappa 
marker 
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b. kappa 
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d. lambda 
Figure 5: IHC reports shows tumor cell expressed (a)cd 
20 (b) kappa (c)ki67 (d) lambda markers positive 
DISCUSSION 
Plasmablastic lymphoma is a rare, aggressive HIV as-
sociated NHL and also significantly present with EBV 
coinfection. Non – Hodgkin lymphoma is the most 
common HIV related neoplasm after kaopsi’s sar-
coma. The risk of developing NHL is 80 – 100 times 
greater in HIV – positive patients than otherwise 
healthy persons8. Review of literature suggests that 
PBL accounts 2.6% of cases of HIV associated NHL6. 
Review of literature suggests that 31% of cases in-
volves HIV negative patients and among HIV negative 
patients, 33 % patients are with other causes of im-
munodeficiency such as iatrogenic immunosuppres-
sion in the context of solid organ transplantation or 
in elderly patients [9, 10,11] 
The first 16 cases were described by Delecluse et al in 
1997 as a highly malignant diffuse large B cell lym-
phoma (DLBCL) of oral cavity. PBL may also involve 
lung, nasal cavity, stomach, skin and within sacro-
occygeal cysts[3,12]. 
Cases of HIV negative PBL may also arise from previ-
ously existing lymphoproliferative or autoimmune 
disorders[9,13]. However, 35% of cases have been 
noted in immunocompetent patients in a recent 
meta-analysis.  
PBL is characterized as an aggressive rare clinico-
pathologic variant of DLBCL. It shows cell with the 
blastoid morphology and immunophenotype resem-
bling plasmablasts. Plasmablasts constitute a negligi-
ble amount of lymphoid tissue and hence have not 
drawn much attention[2,8] Plasmablasts count is sig-
nificantly raised in lymphadenopathies caused by ru-
bella virus, or EBV (infectious mononucleosis)[14,15]. 
Because of the described similarity between reactive 
plasmablasts and an antigenic profile similar to 
plasma cells, Delecluse et al.[2] proposed the name 
Plasmablastic lymphoma.  
Recently the WHO classification listed PBL as a vari-
ant of DLBCL and HIV related lymphoma[16]. PBL is a 
molecularly heterogenous disease derived from post 
germinal centre cells[8].  
In the present case, patient was 82 years old male and 
HIV negative. PBL usually presents in the second and 
fifth decades of life; mean age for PBL is 40 years[7] 
with male predominance with 70 % to 80 % of cases. 
There was a 5.8:1 ratio of male to female patients8. 
HIV negative PBL occurs mostly in older patients due 
to immunodeficiency.  
 With respect to clinical staging, stage IV was the most 
common and stage I was the second most common[3]. 
Maxilla more frequently involve than mandible. In 
most cases lesion presents as rapidly growing some-
times destructive. Lesion presents as a solitary, soft 
asymptomatic swelling, which is non characteristic 
for the lesion, presenting a dilemma for the diagnos-
tician[1]. In this case mandible is involved extending 
up to to ramus which is a rare occurrence, lesion was 
firm and asymptomatic.  
The lesion is often misdiagnosed as gingival enlarge-
ment like pyogenic granuloma and peripheral giant 
cell granuloma[17], odontogenic inflammatory pro-
cess, anaplastic plamacytoma, tumours of the salivary 
gland or jaws, or even squamous cell carcinoma[1]. 
The diagnosis should be based on morphological, cy-
tological and immunohistology investigations. 
Histopathologically, PBL is characterized by cellular 
proliferation of large lymphoid cells in a sheet – like 
growth pattern. The sheets of tumour cell are inter-
spersed with body macrophages, resulting in a ‘starry 
sky ‘appearance on low power examination. The tu-
mour cells are reminiscent of immunoblasts and plas-
mablastic differentiation in the form of a round to 
oval shape with eccentrically placed nuclei and abun-
dant eosinophilic cytoplasm. Usually, a single promi-
nent nucleolus is located in the centre of the nucleus. 
They show a brisk mitotic index and sometimes ne-
crosis. Mature lymphoid cells, neutrophils and few 
eosinophils may be present[18].  
Carcinoma can be distinguished from PBL by the 
presence of immunoreactivity for cytokeratin. PBL 
has a terminally differentiated B-cell immunopheno-
type, characterised by absent expression of leucocyte 
common antigen and B-cell antigens. The tumour 
cells in PBL are immunoreactive for CD 138, a mem-
ber of the transmembrane heparan sulphate proteo-
glycan family, has a role in plasma cell adherence to 
bone marrow stromal matrix[19]. The tumour also 
shows immunoreactivity for VS38c, IgG, Ki-67, CD 38, 
EBV and monotypic light chain positivity for kappa or 
lambda and do not exhibit immunoreactivity for CD 
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20, CD 45RO, CD 30, CD 3, CD 10[18].The case pre-
sented here shows immunoreactivity for CD 138, 
patchy positive for CD 20, K 167 and kappa light 
chain.  
Differential diagnosis for oral PBL includes poorly 
differentiated carcinoma, amelanotic melanoma, 
other lymphoproliferative diseases, plasmacytoma 
and small non cleaved lymphoma[8].  
PBL is a therapeutic challenge with a clinical course 
characterized by a high rate of relapse and death[11]. 
Oral PBL patient have been treated heterogeneously 
as there is no standard treatment for PBL. 
The treatment may consist of chemotherapy; CHOP 
(cyclophosphamide, doxorubicin, vincristine and 
prednisone) or local excision followed by radiation. 
Current guidelines recommend more intensive regi-
men as use of CHOP is considered inadequate. The 
National Comprehensive Cancer Network 
(NCCN)recommends dose-adjusted EPOCH (etopo-
side, vincristine, doxorubicin, cyclophosphamide, 
and prednisone), CODOX-M/IVAC (cyclophospha-
mide, vincristine, doxorubicin, methotrexate alter-
nating with ifosfamide, etoposide, and cytarabine), or 
Hyper-CVAD (hyperfractionated cyclophosphamide, 
vincristine, doxorubicin, and dexamethasone alter-
nating with methotrexate and cytarabine)[20,21]. Re-
cent studies focused on use of bortezomib, a pro-
teasome inhibitor[22]. Castillo et al23 were the first to 
report the successful addition of bortezomib to the 
EPOCH regimen. Also, Bortezomib is an active agent 
in plasma-cell myeloma. 
The outcome of untreated patients with PBL is dismal 
with a median overall survival rate of 3 months for 
HIV positive patients and 4 months for HIV negative 
patients[21,24]. The prognosis of PBL is poor despite of 
its site of origin and death usually occurs 1 – 24 
months after diagnosis, the average survival rate is 6 
months. 
In this case, surgery was not opted and chemotherapy 
was proposed as a treatment plan as patient was 
older and due to generalised involvement of bone. In 
our patient, Bortezomib 2mg was given on days 1,8, 
15, 22. This patient shows significant response to the 
chemotherapy as lesion regressed after the treatment 
and patient was in stable condition. Patient with lo-
calized disease has better prognosis. In this case the 
anticipated prognosis might be poor. Although the 
prognosis is worse in HIV positive patients but ac-
cording to recent meta analysis there is no significant 
difference in the survival rate among HIV positive and 
HIV negative patients. 
CONCLUSION 
PBL is a rare and aggressive lesion, most commonly 
occur in HIV positive patients but it also occur in HIV 
negative patients, with a significant proportion of 
cases occurring in post- transplant and immunocom-
petent patients. It is frequently occur in maxilla but 
this case involves mandible, a rare finding. Immuno-
histochemistry and correlation with clinical findings 
are crucial for establishing a correct diagnosis. Treat-
ment has been centered on CHOP chemotherapy with 
good response, however, more intensive therapies 
are recommended. Recent case reports of a good clin-
ical response to bortezomib are encouraging. 
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